Historical record - last NADAC effective date: 12/22/2021
Product Information
AMLODIPINE-BENAZEPRIL 5-20 MG is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $0.1318 per EA under NDC 68180075701. Its NADAC has been published 422 times since Nov 28, 2013.
FDA first approved this application on Feb 5, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5; 20 mg/1; mg/1
Manufacturer
Lupin Pharmaceuticals Inc.NDC
68180075701
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
12/22/2021
Active Ingredients
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA078466FDA Approved
2/5/2010
TE Code
AB
On Market Since
2/5/2010
Pharmacological Classes
Price Statistics
The NADAC for AMLODIPINE-BENAZEPRIL 5-20 MG has been published 422 times since Nov 28, 2013, and over the history we have for it it has declined 72.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1318 per EA |
|---|---|
| All-time high | $0.4743 (Dec 11, 2013) |
| All-time low | $0.1108 (Sep 18, 2019) |
| Median price | $0.1942 |
| Average price | $0.2263 |
| Largest weekly change | +18.2% (Jan 22, 2020) |
| Weeks tracked | 422 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
+2.9%
All
-72.2%
Last surveyed Dec 22, 2021 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 21% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Amlodipine Besylate and Benazepril Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin Converting Enzyme Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AMLODIPINE-BENAZEPRIL 5-20 MG?
The current National Average Drug Acquisition Cost (NADAC) for AMLODIPINE-BENAZEPRIL 5-20 MG, manufactured by Lupin Pharmaceuticals Inc., is $0.1318 per EA (NDC 68180075701), effective Dec 22, 2021.
How has the price of AMLODIPINE-BENAZEPRIL 5-20 MG changed over time?
Over the history we have for it, the NADAC for AMLODIPINE-BENAZEPRIL 5-20 MG has declined 72.2%. It has been tracked across 422 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for AMLODIPINE-BENAZEPRIL 5-20 MG?
Since Nov 28, 2013, the NADAC for AMLODIPINE-BENAZEPRIL 5-20 MG has ranged from a low of $0.1108 (Sep 18, 2019) to a high of $0.4743 (Dec 11, 2013), with a median of $0.1942 per EA.
Are there cheaper alternatives to AMLODIPINE-BENAZEPRIL 5-20 MG?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, AMLODIPINE-BENAZEPRIL 5-20 MG, is $0.1035 per EA — about 21% below AMLODIPINE-BENAZEPRIL 5-20 MG.
Who manufactures AMLODIPINE-BENAZEPRIL 5-20 MG?
AMLODIPINE-BENAZEPRIL 5-20 MG (NDC 68180075701) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.